Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3108267 | 0.89 | MAPK14 (0.66) | MAPK14MCHR1 | |
| SCHEMBL3113149 | 0.87 | MAPK14 (0.66) | MAPK14MCHR1 | |
| SCHEMBL3108389 | 0.87 | MAPK14 (0.55) | MAPK14MCHR1 | |
| SCHEMBL3339442 | 0.87 | MAPK14 (0.51) | MAPK14MCHR1 | |
| SCHEMBL1140587 | 0.87 | MAPK14 (0.64) | MAPK14 | |
| SCHEMBL1140442 | 0.86 | MAPK14 (0.50) | MAPK14 | |
| SCHEMBL3341669 | 0.86 | MAPK14 (0.52) | MAPK14MCHR1 | |
| Hydrochloric Acid SCHEMBL1140377 | 0.86 | MAPK14 (0.64) | MAPK14 | |
| SCHEMBL1140402 | 0.86 | MAPK14 (0.65) | MAPK14 | |
| SCHEMBL1140310 | 0.84 | MAPK14 (0.65) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1682520-B1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2011-02-23 | — | — | EP | claimed |
| US-7750154-B2 | Amide derivatives | ASTRAZENECA AB (SE) | 2010-07-06 | — | — | US | claimed |
| JP-2007509118-A | — | — | 2007-04-12 | — | — | JP | claimed |
| US-20070043065-A1 | Amide derivatives | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | US | claimed |
| EP-1682520-A1 | AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2006-07-26 | — | — | EP | claimed |
| WO-2005042502-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-05-12 | — | — | WO | claimed |
| US-7750154-B2 | Amide derivatives | ASTRAZENECA AB (SE) | 2010-07-06 | — | — | US | disclosed |
| US-20070043065-A1 | Amide derivatives | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043065-A1 | Amide derivatives | IL6, IL2, IL1B | MAPK14 2518/4885MCHR1 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.